Under the agreement, SRI’s Center for Neuroscience and Metabolic Diseases will use Inscopix’s nVista HD imaging system to understand function of a normal brain and the dysfunctions of neural circuitry that underlie neurological and neuropsychiatric disorders.

SRI’s Center for Neuroscience and Metabolic Diseases senior director Thomas Kilduff said Inscopix’s nVista HD technology will provide SRI researchers with an unparalleled view into brain activity that underlies both normal and diseased brain function.

"Since many brain diseases such as Alzheimer’s, autism, and schizophrenia are thought to involve dysfunction of neural circuitry, we expect to obtain novel insights that may lead to new therapeutic avenues for the treatment of neurological and neuropsychiatric disorders," Kilduff added.

Inscopix CEO Kunal Ghosh said the company’s continued technology and application development will benefit via the project.

"At the same time Inscopix’s scientists are also looking forward to working with SRI’s researchers on pursuing new science uniquely enabled by nVista HD," Ghosh added.